(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 May 2013 (10.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/067022 A1

(51) International Patent Classification:
A61K 9/19 (2006.01) *A61K 47/10* (2006.01)
A61K 9/08 (2006.01) *A61K 47/12* (2006.01)
A61K 38/22 (2006.01) *A61K 47/14* (2006.01)
A61K 38/26 (2006.01) *A61K 47/18* (2006.01)
A61K 38/28 (2006.01) *A61K 47/20* (2006.01)
A61K 9/00 (2006.01) *A61K 47/22* (2006.01)
A61K 47/02 (2006.01)

(21) International Application Number:
PCT/US2012/062816

(22) International Filing Date:
31 October 2012 (31.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/553,388 31 October 2011 (31.10.2011) US
61/609,123 9 March 2012 (09.03.2012) US

(71) Applicant: **XERIS PHARMACEUTICALS, INC.** [US/US]; 3935 W. Breaker Lane, Third Floor, Austin, TX 78759 (US).

(72) Inventors: **PRESTRELSKI, Steven**; c/o Xeris Pharmaceuticals, Inc., 3935 W. Breaker Lane, Third Floor, Austin, TX 78759 (US). **SCOTT, Nancy**; c/o Xeris Pharmaceuticals, Inc., 3935 W. Breaker Lane, Third Floor, Austin, TX 78759 (US).

(74) Agent: **KRAWZSENEK, Michael, R.**; 98 San Jacinto Boulevard, Suite 1100, Austin, TX 78701-4255 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2013/067022 A1

(54) Title: FORMULATIONS FOR THE TREATMENT OF DIABETES

(57) Abstract: Disclosed is a formulation for parenteral administration comprising insulin that comprises a pH memory between 1 to 4 or between 6 to 8 and an aprotic polar solvent, wherein the insulin is solubilized in the aprotic polar solvent, wherein the solubilized insulin comprises stable monomeric or dimeric forms of insulin or mixtures thereof, and wherein the water content of the formulation is equal to or less than 15% w/v.